Bruker Daltonics and Protein Discovery Announce MALDI Molecular Imaging Mass Spectrometry Co-Marketing Agreement.BILLERICA, Mass. & KNOXVILLE, Tenn. -- Bruker Daltonics Inc. and Protein Discovery, Inc. announce today that they intend to collaborate on introducing scientists to the protein biomarker discovery capabilities of MALDI MALDI Matrix-Assisted Laser Desorption/Ionization molecular imaging mass spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. . Protein Discovery holds a license from Vanderbilt University to provide imaging mass spectrometry services, and provides these services to customers in the research, pharmaceutical and diagnostics industries. Bruker Daltonics manufactures and sells the MALDI Molecular Imager(TM) (for research use only) that has been optimized for this technique in collaboration with Professor Richard Caprioli at Vanderbilt University. Both companies anticipate significant synergy effects from the collaboration, as both expect to benefit from the increasing popularity of MALDI imaging mass spectrometry. MALDI molecular imaging mass spectrometry reads cell type specific protein and peptide mass spectra directly from sliced tissues. The imaging resolution of the technique enables differential mass spectrometry analysis of adjacent tissue types within a single tissue slice, such as cancerous vs. non-cancerous regions. MALDI imaging mass spectrometry is very promising for research and discovery of future diagnostic and prognostic protein biomarkers. Protein Discovery's MALDI imaging mass spectrometry service laboratory is outfitted with Bruker Daltonics' instrumentation. "The capabilities and applications of MALDI imaging mass spectrometry have now been well documented in the scientific literature by researchers who picked up on it early," said Chuck Witkowski, chief executive officer at Protein Discovery. "However, until recently, there was little vendor support for imaging mass spectrometry, so biologists and research clinicians couldn't really see what the technique could accomplish for their own research. With the Bruker Daltonics MALDI Molecular Imager we now can show them the power of this new technique on their own research samples. We're already conducting a number of pilot-scale projects for research groups looking for Looking for In the context of general equities, this describing a buy interest in which a dealer is asked to offer stock, often involving a capital commitment. Antithesis of in touch with. cell type specific protein spectra that they can map directly onto a histological tissue slice image." Dr. Michael Schubert, Executive Vice President of Bruker Daltonics, stated: "Our recently introduced MALDI Molecular Imager is the leading mass spectrometry platform for imaging the spatial distribution of peptide and protein biomarkers in tissue sections. Enabled by our unique and proprietary smartbeam(TM) technology, the MALDI Molecular Imager generates results very quickly and with unrivalled data quality. Visualization of the spatial distribution of peptides and proteins is a powerful new tool in the fields of biomarker validation and drug development. Protein Discovery has significant expertise in applying MALDI molecular imaging mass spectrometry and we are very pleased to enter into this partnership with them." ABOUT PROTEIN DISCOVERY Protein Discovery, Inc. develops and markets mass spectrometry sample preparation products and services. The company's solutions simplify sample preparation, increase sample throughput, improve data quality, and accelerate the development and adoption of mass spectrometry as a routine analytical and clinical technique. Protein Discovery is privately held and located in Knoxville, Tennessee. For additional information, please visit www.proteindiscovery.com. ABOUT BRUKER BIOSCIENCES (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BRKR BRKR Breaker ) Bruker BioSciences Corporation Bruker Biosciences Corporation is a Massachusetts-based company formed in 2003 which develops and manufactures scientific instrumentation for academic research and industrial use. , headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis tools. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker Daltonics also offers a broad line of nuclear, biological and chemical (NBC NBC in full National Broadcasting Co. Major U.S. commercial broadcasting company. It was formed in 1926 by RCA Corp., General Electric Co. (GE), and Westinghouse and was the first U.S. company to operate a broadcast network. ) detection products for defense and homeland security. For more information, please visit www.bdal.com and www.bruker-biosciences.com. CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, exposure to currency fluctuations, changes in governmental regulations, capital spending capital spending Spending for long-term assets such as factories, equipment, machinery, and buildings that permits the production of more goods and services in future years. and government funding policies, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. , our most recent quarterly reports on Form 10-Q Form 10-Q See 10-Q. , and our current reports on Form 8-K Form 8-K The form required by the SEC when a publicly held company incurs any event that might affect its financial situation or the share value of its stock. Form 8-K See 8-K. . We disclaim any intent or obligation to update these forward-looking statements. All products are for research use only. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion